1. Home
  2. VST vs REGN Comparison

VST vs REGN Comparison

Compare VST & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vistra Corp.

VST

Vistra Corp.

HOLD

Current Price

$168.50

Market Cap

71.0B

Sector

Utilities

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$755.77

Market Cap

73.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VST
REGN
Founded
1882
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.0B
73.9B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
VST
REGN
Price
$168.50
$755.77
Analyst Decision
Buy
Buy
Analyst Count
11
23
Target Price
$234.09
$795.74
AVG Volume (30 Days)
4.1M
1.1M
Earning Date
11-06-2025
02-03-2026
Dividend Yield
0.53%
0.47%
EPS Growth
N/A
2.88
EPS
2.77
41.59
Revenue
$17,191,000,000.00
$14,247,800,000.00
Revenue This Year
$15.69
$1.95
Revenue Next Year
$13.95
$5.47
P/E Ratio
$61.31
$17.82
Revenue Growth
5.69
2.89
52 Week Low
$90.51
$476.49
52 Week High
$219.82
$790.98

Technical Indicators

Market Signals
Indicator
VST
REGN
Relative Strength Index (RSI) 43.54 61.81
Support Level $158.65 $689.88
Resistance Level $180.00 $753.61
Average True Range (ATR) 6.86 20.54
MACD 0.56 -4.09
Stochastic Oscillator 45.23 65.15

Price Performance

Historical Comparison
VST
REGN

About VST Vistra Corp.

Vistra Corp. is one of the largest power producers and retail energy providers in the US. Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, solar, and energy storage assets. The Lotus Partners asset purchase would add 2.6 GW of natural gas generation. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: